KR920017643A - 약제학적 에어로졸 제제 - Google Patents

약제학적 에어로졸 제제 Download PDF

Info

Publication number
KR920017643A
KR920017643A KR1019920004118A KR920004118A KR920017643A KR 920017643 A KR920017643 A KR 920017643A KR 1019920004118 A KR1019920004118 A KR 1019920004118A KR 920004118 A KR920004118 A KR 920004118A KR 920017643 A KR920017643 A KR 920017643A
Authority
KR
South Korea
Prior art keywords
group
aerosol formulation
active ingredient
propellant
pharmaceutically active
Prior art date
Application number
KR1019920004118A
Other languages
English (en)
Inventor
켈러 만프레트
허조크 쿠르트
Original Assignee
베르너 발데크
시바-가이기 에이지
하. 마이어·엘. 수포르
야고 파르마 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 에이지, 하. 마이어·엘. 수포르, 야고 파르마 에이지 filed Critical 베르너 발데크
Publication of KR920017643A publication Critical patent/KR920017643A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

약제학적 에어로졸 제제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. (a)비치환된 탄화수소 및 부분적으로나 완전하게 불소처리된 탄화수소로 이루어진 그룹으로부터의 1바 내지 6바(20℃)의 증기압을 갖는 액화된 추진 가스 또는 추진 가스 혼합물, (b)모노 아세틸화되거나 디아세틸화된 모노글리세라이드로 이루어진 그루바으로부터의 비-이온성 계면활성제, (c)약제학적 활성 성분 또는 활성 성분 배합물 및, 임의의 (d)에어로졸 제제에 적합한 기타의 통상의 약제학적 부형제를 함유하는 에어로졸로서 사용하기 위한 약제학적 조성물.
  2. 제1항에 있어서, (a)프로판, n-부탄, 이소부탄, 디-, 트리-, 또는 테트라플루오로에탄(134a) 및 헵타플루오로프로판(227)로 이루어진 그룹으로부터의 추진 가스 또는 추진 가스 혼합물, (b)모노아세틸화된 모노글리세라이드로 이루어진 그룹으로부터의 비-이온성 계면활성제, (c)항알레르기제, 베타 교감 신경 흥분제, 항콜린제 및 코르티코이드로 이루어진 그룹으로부터의 약제학적 활성성분 또는 활성성분 배합물 및, 임의의 (d)에어로졸 제제에 적합한 추가의 통상적인 약제학적 부형제를 함유하는 약제학적 조성물.
  3. 제1항에 있어서, (a)프로판, n-부탄, 이소부탄, 테트라플루오로에탄(134a) 및 헵타플루오로프로판(227)로 이루어진 그룹으로부터의 추진 가스 또는 추진 가스 혼합물, (b)모노아세틸화된 모노글리세라이드 그룹으로부터의 비-이온성 계면활성제, (c)이나트륨, 크로모글리케이트, 살부타몰, 살메테롤, 포르모테롤, 옥시트로피퓸, 브로마이드, 이프라로퓸, 브로마이드, 부데소나이드, 플루니솔리드, 베클로메타손 및 트리암시놀론으로 이루어진 그룹으로부터의 약제학적 활성성분 또는 활성성분 배합물 및, 임의의 (d)에어로졸 제제에 적합한 추가의 통상적인 약제학적 부형제를 함유하는 약제학적 조성물.
  4. 제1항에 있어서, (a)추진 가스 헵타플루오로프로판(227), (b)모노아세틸화된 모노글리세라이드로 이루어진 그룹으로부터의 비-이온성 계면활성제, (c)이나트륨 크로모글리케이트, 살부타몰, 살메테롤, 포르모테롤. 옥시트로퓸 브로마이드, 이프라트로퓸 브로마이드, 부데소나이드, 플루니솔리드, 베클로메타손 및 트리암시놀론으로 이루어진 그룹으로 부터의 약제학적 활성성분 또는 활성성분 배합물 및, 임의의 (d)에어로졸 제제에 적합한 추가의 통상적인 약제학적 부형제를 함유하는 약제학적 조성물.
  5. 약제학적 활성 성분 또는 활성 성분의 배합물 (c)을 내압용기에 넣고, 목적하는 단계 순서로 비-이온성 계면활성제 (b), 필요한 경우 통상의 약제학적 부형제(d)를 도입한 후, 추진 가스 또는 추진 가스 혼합물(a)을 도입하고, 균질화시키며, 균질화된 혼합물을 에어로졸 제제에 적합한 투여 용기에 도입함을 특징으로하여, 제1항에 따른 약제학적 조성물을 제조하는 방법.
  6. 제1항에 있어서 사람 또는 동물의 치료시 에어로졸 제제로서 사용하기 위한 약제학적 조성물.
  7. 제1항에 있어서, 기도 장애 치료를 위해 비강 또는 구강 흡입 요법에서 에어로졸 제제로서 사용하기 위한 약제학적 조성물.
  8. 에어로졸 제제로서 사용될 수 있는 약제학적 조성물의 제조를 위한 모노아세틸화되거나 디아세틸화된 모노글리세라이드 그룹으로부터의 비-이온성 게면활성제의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920004118A 1991-03-14 1992-03-13 약제학적 에어로졸 제제 KR920017643A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH78191 1991-03-14
CH00781/91-2 1991-03-14

Publications (1)

Publication Number Publication Date
KR920017643A true KR920017643A (ko) 1992-10-21

Family

ID=4195038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920004118A KR920017643A (ko) 1991-03-14 1992-03-13 약제학적 에어로졸 제제

Country Status (13)

Country Link
EP (1) EP0504112A3 (ko)
JP (1) JPH04327527A (ko)
KR (1) KR920017643A (ko)
AU (1) AU646723B2 (ko)
CA (1) CA2062854A1 (ko)
FI (1) FI921060A (ko)
HU (1) HU208398B (ko)
IE (1) IE920826A1 (ko)
IL (1) IL101169A0 (ko)
MX (1) MX9201082A (ko)
NO (1) NO920987L (ko)
NZ (1) NZ241938A (ko)
ZA (1) ZA921877B (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
WO1992022287A1 (en) 1991-06-10 1992-12-23 Schering Corporation Non-chlorofluorocarbon aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
DE4132176C2 (de) * 1991-09-27 1997-03-13 Ig Spruehtechnik Gmbh Dosieraerosole mit Isobutan als Treibmittel
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
CA2421976C (en) 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
ATE260641T1 (de) 1991-12-18 2004-03-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
EP0550031B1 (de) * 1991-12-31 1996-05-08 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
ATE177941T1 (de) * 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
ES2138074T3 (es) * 1993-03-29 2000-01-01 Lynchris Pharm Ltd Aerosol anestesico en base a lidocaina.
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
NZ276637A (en) * 1993-12-20 1997-07-27 Minnesota Mining & Mfg Aerosol containing flunisolide, ethanol, and tetrafluoroethane and/or heptafluoropropane propellant
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
JPH09510445A (ja) * 1994-03-14 1997-10-21 アボツト・ラボラトリーズ ビタミンｅ含有エアゾル医薬組成物
DE69637257T2 (de) 1995-04-14 2008-06-12 Smithkline Beecham Corp. Verfahren zur Herstellung eines Dosierinhalators
KR19980703850A (ko) 1995-04-14 1998-12-05 그레이엄브레레톤 베클로메타손 디프로피오네이트용 계량 흡입기
RO119117B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator cu doză fixă pentru fluticazon propionat
JPH11509434A (ja) * 1995-04-14 1999-08-24 グラクソ、ウェルカム、インコーポレーテッド サルメテロール用計量投与用吸入器
RU2223750C2 (ru) 1995-06-27 2004-02-20 Берингер Ингельхайм КГ Лекарственная композиция в виде раствора, предназначенная для получения способного к ингаляции аэрозоля
GB9526392D0 (en) * 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9620187D0 (en) † 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
JP2001511160A (ja) 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
WO1998037894A1 (de) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999025786A1 (en) * 1997-11-18 1999-05-27 Alliedsignal Inc. Hydrofluorocarbon refrigerants
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ES2234266T3 (es) 1998-07-24 2005-06-16 Jago Research Ag Formulaciones medicas para aerosoles.
WO2000007567A1 (de) 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911064A1 (de) * 1999-03-12 2000-09-14 Ig Spruehtechnik Gmbh Dosieraerosole mit Isobutan als Treibmittel
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
MXPA02011414A (es) 2000-05-22 2003-06-06 Chiesi Farma Spa Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
AU2002221741B2 (en) * 2000-10-31 2007-04-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative solution formulation containing a tiotropium salt
WO2002036106A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden
EP1273292B1 (en) 2001-07-02 2004-05-26 CHIESI FARMACEUTICI S.p.A. Optimised formulation of tobramycin for aerosolization
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
BRPI0407368A (pt) * 2003-02-10 2006-02-14 Bayer Healthcare Ag tratamento de doenças bacterianas dos órgãos respiratórios mediante aplicação local e fluor-quinolonas.
US8435497B2 (en) 2003-06-13 2013-05-07 Takeda Gmbh Formoterol of and ciclesonide combination
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8227027B2 (en) 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8444873B2 (en) 2009-06-12 2013-05-21 Solvay Fluor Gmbh Refrigerant composition
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
SE8505048L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Nutritionsemulsion med syretransporterande egenskaper
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations

Also Published As

Publication number Publication date
IL101169A0 (en) 1992-11-15
HU9200850D0 (en) 1992-05-28
AU1218892A (en) 1992-09-17
FI921060A0 (fi) 1992-03-11
MX9201082A (es) 1992-09-01
NZ241938A (en) 1993-06-25
EP0504112A2 (de) 1992-09-16
EP0504112A3 (en) 1993-04-21
IE920826A1 (en) 1992-09-23
HU208398B (en) 1993-10-28
NO920987D0 (no) 1992-03-13
CA2062854A1 (en) 1992-09-15
JPH04327527A (ja) 1992-11-17
AU646723B2 (en) 1994-03-03
FI921060A (fi) 1992-09-15
HUT60430A (en) 1992-09-28
ZA921877B (en) 1992-10-28
NO920987L (no) 1992-09-15

Similar Documents

Publication Publication Date Title
KR920017643A (ko) 약제학적 에어로졸 제제
EP0927032B1 (en) Buccal, non-polar spray for nitroglycerin
ATE216575T1 (de) Treibgasmischung für eine aerosolzubereitung
ES2391563T5 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
EP2210588B1 (en) Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
CA2421976A1 (en) Medicaments
PT656207E (pt) Formulacoes de aerossois sem clorofluorocarbonetos
Newman Metered dose pressurized aerosols and the ozone layer
DK0616525T3 (da) Medikamenter
CA2586146A1 (en) Fluorocarbon aerosol medicaments
AR018183A1 (es) Formulacion terapeutica en aerosol que comprende un agente terapeutico en la forma de particulas recubiertas por lo menos por un excipiente derecubrimiento y por lo menos un surfactante, en suspension en un gas propelente licuado para la administracion de agentes terapeuticos particularmentepor la r
US5415853A (en) Compressed gas packages using polyoxyethylene glyceryl oleates
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
AR009370A1 (es) UNA COMPOSICION FARMACEUTICA EN AEROSOL ADECUADA PARA LA ADMINISTRACION DE BUDESONIDA, UN PRODUCTO FARMACEUTICO QUE LA CONTIENE, UN METODO PARAADMINISTRAR BUDESONIDA Y USO DE UNA MEZCLA DE HFA 134a Y HFA 227
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
JP2004529108A5 (ko)
US3282791A (en) Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
EP1575559B1 (de) Dosieraerosole mit lecithin als oberflächenaktiver substanz
TH29544B (th) สูตรผสมรูปแบบละอองลอยทางเภสัชกรรมซึ่งมีสารรักษาโรคและตัวผลักดันชนิดไฮโดรฟลูโอโรคาร์บอน
TH13269A (th) สูตรผสมยาละอองลอยทางเภสัชซึ่งประกอบด้วยบีโคลเมธาโซนไดโพรพิโอเนท
ITMI962278A1 (it) Composizioni farmaceutiche spray per l'applicazione di formulati ad uso topico contenenti escina
BR102012008322B1 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid